---
title: "X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291976775.md"
description: "X4 Pharmaceuticals, a company specializing in rare hematology diseases, recently announced the issuance of inducement awards to new employees on July 6, 2026. These awards, granted under the 2019 Inducement Equity Incentive Plan, involve options for a total of 750,000 shares of X4's common stock. The purpose of the 2019 Inducement Plan is to provide equity incentives for individuals who were not previously part of X4's workforce. These inducement awards were approved by X4's Compensation Committee of the Board of Directors and are compliant with Nasdaq Listing Rule 5635(c)(4)."
datetime: "2026-07-07T20:32:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291976775.md)
  - [en](https://longbridge.com/en/news/291976775.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291976775.md)
generator: "portal-rs"
---

# X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals, a company specializing in rare hematology diseases, recently announced the issuance of inducement awards to new employees on July 6, 2026. These awards, granted under the 2019 Inducement Equity Incentive Plan, involve options for a total of 750,000 shares of X4's common stock. The purpose of the 2019 Inducement Plan is to provide equity incentives for individuals who were not previously part of X4's workforce. These inducement awards were approved by X4's Compensation Committee of the Board of Directors and are compliant with Nasdaq Listing Rule 5635(c)(4).

### Related Stocks

- [XFOR.US](https://longbridge.com/en/quote/XFOR.US.md)

## Related News & Research

- [X4 Pharmaceuticals (XFOR) to Release Quarterly Earnings on Thursday](https://longbridge.com/en/news/294330509.md)
- [X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Average Rating of "Moderate Buy" from Analysts](https://longbridge.com/en/news/293817193.md)
- [Pharming Group (NASDAQ:PHAR) Shares Gap Up   - Should You Buy?](https://longbridge.com/en/news/297811201.md)
- [X4 Pharmaceuticals (NASDAQ:XFOR) Releases Earnings Results, Beats Expectations By $0.05 EPS](https://longbridge.com/en/news/295157811.md)
- [13:41 ETNorgine anuncia la autorización de comercialización de la Comisión Europea para XOLREMDI® (mavorixafor)](https://longbridge.com/en/news/284619445.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**